TherapeuticsMD Inc. [TXMD] Revenue clocked in at $90.90 million, down -50.12% YTD: What’s Next?


TherapeuticsMD Inc. [NASDAQ: TXMD] stock went on an upward path that rose over 4.52% on Wednesday, amounting to a one-week price increase of more than 5.07%. The company report on November 11, 2021 that TherapeuticsMD Announces Third Quarter 2021 Financial Results.

– Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 -.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


– ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 -.

Over the last 12 months, TXMD stock dropped by -54.96%. The one-year TherapeuticsMD Inc. stock forecast points to a potential upside of 86.67. The average equity rating for TXMD stock is currently 1.70, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $263.76 million, with 422.22 million shares outstanding and 396.39 million shares in the current float. Compared to the average trading volume of 4.39M shares, TXMD stock reached a trading volume of 2581501 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on TherapeuticsMD Inc. [TXMD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TXMD shares is $4.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TXMD stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Jefferies have made an estimate for TherapeuticsMD Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on August 07, 2020. The new note on the price target was released on May 19, 2020, representing the official price target for TherapeuticsMD Inc. stock.

The Average True Range (ATR) for TherapeuticsMD Inc. is set at 0.04, with the Price to Sales ratio for TXMD stock in the period of the last 12 months amounting to 2.90.

TXMD Stock Performance Analysis:

TherapeuticsMD Inc. [TXMD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.07. With this latest performance, TXMD shares dropped by -21.60% in over the last four-week period, additionally sinking by -51.71% over the last 6 months – not to mention a drop of -54.96% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TXMD stock in for the last two-week period is set at 37.19, with the RSI for the last a single of trading hit 38.10, and the three-weeks RSI is set at 37.91 for TherapeuticsMD Inc. [TXMD]. The present Moving Average for the last 50 days of trading for this stock 0.7088, while it was recorded at 0.5849 for the last single week of trading, and 1.0650 for the last 200 days.

Insight into TherapeuticsMD Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and TherapeuticsMD Inc. [TXMD] shares currently have an operating margin of -239.76 and a Gross Margin at +73.77. TherapeuticsMD Inc.’s Net Margin is presently recorded at -282.90.

Return on Total Capital for TXMD is now -91.74, given the latest momentum, and Return on Invested Capital for the company is -109.45. Additionally, TXMD Total Debt to Total Capital is recorded at 199.50, with Total Debt to Total Assets ending up at 136.90.

Reflecting on the efficiency of the workforce at the company, TherapeuticsMD Inc. [TXMD] managed to generate an average of -$458,810 per employee. Receivables Turnover for the company is 2.29 with a Total Asset Turnover recorded at a value of 0.29.TherapeuticsMD Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.80 and a Current Ratio set at 1.90.


With the latest financial reports released by the company, TherapeuticsMD Inc. posted -0.15/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -50.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TXMD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TherapeuticsMD Inc. go to 17.60%.

>> 7 Top Picks for the Post-Pandemic Economy <<

TherapeuticsMD Inc. [TXMD] Insider Position Details

There are presently around $80 million, or 37.00% of TXMD stock, in the hands of institutional investors. The top three institutional holders of TXMD stocks are: BLACKROCK INC. with ownership of 25,306,542, which is approximately 1.878% of the company’s market cap and around 0.60% of the total institutional ownership; VANGUARD GROUP INC, holding 18,910,787 shares of the stock with an approximate value of $11.42 million in TXMD stocks shares; and FMR LLC, currently with $8.42 million in TXMD stock with ownership of nearly 0.357% of the company’s market capitalization.

Positions in TherapeuticsMD Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 74 institutional holders increased their position in TherapeuticsMD Inc. [NASDAQ:TXMD] by around 11,796,251 shares. Additionally, 57 investors decreased positions by around 47,164,514 shares, while 44 investors held positions by with 74,310,867 shares. The mentioned changes placed institutional holdings at 133,271,632 shares, according to the latest SEC report filing. TXMD stock had 21 new institutional investments in for a total of 3,914,474 shares, while 23 institutional investors sold positions of 19,274,462 shares during the same period.